Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer: Therapeutic implications

Advances in Experimental Medicine and Biology

Volumn 407, Issue , 1996, Pages 41-53

  Gao, Xiang ^a   Porter, Arthur T ^a   Honn, Kenneth V ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE;

CARCINOGENESIS; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CONFERENCE PAPER; DEMOGRAPHY; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; TARGET CELL; TUMOR SUPPRESSOR GENE;

12-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; ARACHIDONATE 12-LIPOXYGENASE; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME MAPPING; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, APC; GENES, DCC; GENES, TUMOR SUPPRESSOR; HUMANS; LOSS OF HETEROZYGOSITY; MALE; NEOPLASM PROTEINS; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0030423102     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (79)

1. X. Gao, and K.V. Honn. Recessive oncogenes: Current status. Pathol. Oncol. Res. 1:7-22 (1995).
2. X. Gao, A.T. Porter, and K.V. Honn. Tumor suppressor genes and their involvement in human prostate cancer. Cancer Mol. Biol. 2:475-498 (1995).
3. B. Vogelstein, E.R. Fearon, S.E. Kern, S.R. Hamilton, C. Preisinger, Y. Nakamura, and R. White. Allelotype of colorectal carcinomas. Science (Washington DC) 244:207-211 (1989).
4. R. Bookstein, J-Y. Shew, P.-L. Chen, P. Scully, and W.H. Lee. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science (Washington DC) 247:712-715 (1990).
5. R. Bookstein, P. Rio, and S. Madreperla. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc. Natl. Acad. Sci. USA. 87:7762-7766 (1990).
6. F.H. Sarkar, W. Sakr, and Y.-W. Li. Analysis of retinoblastoma (RB) gene deletion in human prostatic carcinomas. Prostate 21:145-152 (1992).
7. S.M.A. Phillips, D.G. Morton, S.J. Lee, D.M.A. Wallace, and J.P. Neoptolemos, Loss of heterozygosity of the retinoblastoma and adenomatous polyposis succeptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Brit. J. Urol. 73:390-395 (1994).
8. B.S. Carter, C.M. Ewing, W.S. Ward, B.F. Treiger, T.W. Aalders, J.A. Schalken, J.I. Epstein, and W.B. Isaacs. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Natl. Acad. Sci. USA. 87:8751-8755 (1990).
9. W.B. Isaacs, B.S. Carter, and C.M. Ewing. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res., 51:4716-4720 (1991).
10. B. Vogelstein, and K.W. Kinzler. X-rays strike p53 again. Nature 370:174-175 (1994).
11. E. White. p53, guardian of Rb. Nature 371:21-22 (1994).
12. M.S. Greenblatt, W.P. Bennett, M. Hollstein, and C.C. Harris. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54:4855-4878 (1994).
13. P.J. Van Veldhuizen, R. Sadasivan, F. Garcia, M. S. Austenfeld, and R.L. Stephens. Muatnt p53 expression in prostate carcinoma. Prostate 22:23-30 (1993).
14. P.J. Van Veldhuizen, R. Sadasivan, R. Cherian, T. Dwyer, and R.L. Stephens. p53 expression in incidental prostatic cancer. Am. J. Med. Sci. 305:275-279 (1993).
15. Y. Soini, P. Päakkö, K. Nuorva, D. Kamel, D.P. Lane, and K. Vahakangas. Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Arch. A. Pathol. Anat. Histopathol. 421:223-228 (1992).
16. P.J. Effert, R.H. McCoy, P.J. Walther, E.T. Lui. p53 gene alterations in human prostate carcinoma. J. Urol. 150:257-261 (1993).
17. S.J. Thompson, K. Mellon, R.G. Charlton, C. Marsh, M. Robinson andD.E. Neal. P53 and Ki-67 immunoreactivity in human prostate cancer and benign hyper-plasia. Br. J. Urol. 69:609-613 (1992).
18. M. Watanabe, T. Ushijima, H. Kakiuchin T. Shiraishi, R. Yatani, J. Shimazaki, T. Dotake, T. Sugimrua, and M. Nagao. p53 gene mutations in human prostate cancers in Japan: Different mutation spectra between Japan and Western countries. Jap. J. Cancer Res. 85:904-910 (1994).
19. M. Ittmann, R. Wieczorek, P. Heller, A. Dave, J. Provet, and J. Krolewski. Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. Am. J. Pathol. 145:287-293 (1994).
20. T. Uchida, C. Wada, T. Shitara, S. Egawa, and D. Koshiba. Infrequent involvement of p53 gene-mutations in the tumorigenesis of Japanese prostate-cancer. Brit. J. Cancer 68:751-755 (1993).
21. N.M. Navone, P. Troncoso, L.L. Pisters, T.L. Goodrow, J.L. Palmer, W.W. Nichols, A. von Eschenbach, and C.J. Conti. p53 protein accumulation an gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. 85:1657-1669 (1993).
22. R. Bookstein, D. MacGrogan, S.G. Hilsenbeck, F. Sharkey, and D.C. Allred. p53 is mutated in a subset of advanced stage prostate cancers. Cancer Res. 53:3369-73 (1993).
23. B.V.S. Kallakury, J. Figge, J.S. Ross, H.A.G. Fisher, H.L. Figge, and T.A. Jennings. Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum. Pathol. 25:92-97 (1994).
24. X. Gao, A.T. Porter, J.E. Pontes, and K.V. Honn. Diagnostic and prognostic markers for human prostate cancer. Prostate In press (1996).
25. F.J. Meyers, S.-G. Chi, J.R. Fishman, R.W. deVere White, and P.H. Gumerlock. p53 mutations in benign prosatic hyperplasia. J. Natl. Cancer Inst. 85:1856-1858 (1993).
26. S.-G. Chi, R.W. deVere White, F.J. Meyers, D.B. Siders, F. Lee, P.H. Gumerlock. p53 in prostate cancer: frequent expressed transition mutations. J. Natl. Cancer Inst. 86:926-933 (1994).
27. Y.Q. Chen, X. Gao, D. Grignon, F.H. Sarkr, W. Sakr, K.V. Honn, J.S. Borders, and J.D. Crissman. Multiple mechanisms of p53 inactivation in human prostate cancer. Cancer Mol. Biol. 1:357-367 (1994).
28. X. Gao, K.V. Honn, D. Grignon, W. Sakr, Y.Q. Chen. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostatic carcinomas. Cancer Res. 53:2723-2727 (1993).
29. X. Gao, A. Zacharek, D. Grignon, H. Liu, W. Sakr, A.T. Porter, Y.Q. Chen, and K.V. Honn. High frequency of loss of expression and allelic deletion of the APC and MCC genes in human prostatic carcinomas. Int. J. Oncol. 6:111-117 (1995).
30. E.R. Fearon, K.R. Cho, J.M. Nigro, S.E. Kern, J.W. Simons, J. M. Ruppert, S.R. Hamilton, A.C. Preisinger, G. Thomas, K.W. Kinzler, and B. Vogelstein. Identifi-cation of a chromosome 18q gene that is altered in colorectal carcinoma. Science (Washington DC), 247:49-56 (1990).
31. K.R. Cho, J.D. Oliner, J.W. Simons, L. Hedrick, E.R. Fearon, A.C. Preisinger P. Hedge, G.A. Silverman, and B. Vogelstein. The DCC gene-structural-analysis and mutations in colorectal carcinomas. Genomics, 19:525-531 (1994).
32. L. Hedrick, K.R. Cho, and E.R. Fearon. The DCC gene product in cellular differentiation and colorectal tumorgenesis. Genes Dev. 8:1174-1183 (1994).
33. M.A. Reale, G. Hu, A.I. Zafar, R.H. Getzenberg, S.M. Levine, and E.R. Fearon. Expression and alternative splicing of the deleted in colorectal cancer (DCC) gene in normal and malignant tissues. Cancer Res. 54:4493-4501 (1994).
34. W.E. Pierceall, K.R. Cho, R. H. Getzenberg, M.A. Reale, L. Hedrick, B. Vogelstein, and E.R. Fearon. NIH3T3 cells expressing the deleted in colorectal cancer tumor suppressor gene product stimulate neurite outgrowth in rat PC12 pheochromo-cytoma cells. J Cell Biol. 124:1017-1027. (1994).
35. R. Narayanan, K.G. Lawlor, R.Q. Schaapvel, K.R. Cho, B. Vogelstein, P.B.V. Tran, M.P. Osborne, and N.T. Telang. Antisense RNA to the putative tumor-suppressor gene DCC transforms Rat-1 fibroblasts. Oncogene 7:533-561 (1992).
36. S.F. Brewster S. Browne, and K.W. Brown, Somatic allelic loss at the DCC, APC, NM23-H1 and P53 tumorsuppressor gene loci in human prostatic-carcinoma. J. Urol. 151:1073-1077 (1994).
37. H. Suzuki, S. Aida, S. Akimoto, T. Igarashi, R. Tatani, and J. Shimazaki. State of adenomatous polyposis coli gene and RAS oncogenes in Japanese prostate cancer. Jap. J. Cancer Res. 85:847-852 (1994).
38. X. Gao, N. Wu, D. Grignon, A. Zacharek, H. Liu, A. Salkowski, G. Li, W. Sakr, F. Sarkar, A.T. Porter, Y.Q. Chen, and K.V. Honn. High frequency of mutator phenotype in human prostatic adenocarcinoma. Oncogene 9:2999-3003 (1994).
39. R. Fishel, M. Kay-Lescoe, M.R.S. Rao, N.G. Copeland, N.A. Jenkins, J. Garber, M. Kane, and R. Kolodner. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75:1027-1038 (1993).
40. F.S. Leach, N.C. Nicolaides, N. Paradopoulos, B. Liu, J. Jen, R. Parsons, P. Peltomaki, P. Sistonen, L.A. Altonen, M. Nystrom-Lahti, X Y. Guan, J. Zhang, P.S. Meltzer, W. Yu, F.T. Kao, D.J. Chen, K.M. Cerosaletti, R.E.K. Fournier, S. Todd, T. Lewis, R.J. Leach, S.L. Naylor, J. Weissenbach, J.P. Mecklin, H. Jarvinen, G.M. Petersen, S.R. Hamilton, J. Green, J. Jass, P. Watson, H.T. Lynch, J.M. Trent A. de la Chapelle, K.W. Kinzler, and B. Vogelstein. Mutations of a MutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75:1215-1225 (1993).
41. R.D. Kolodner, N.R. Hall, J. Lipford, M.F. Kane, P.T. Morrison, P.J. Finan, J. Burn, P. Chapman, C. Earabino, E. Merchant, and D.T. Bishop. Structure of teh human MLH1locus and analysis of a large hereditary nonpolyposis colorectal carcinoma kindred for mlh1 mutations. Cancer Res. 55:242-248 (1995).
42. M. Koi, A. Umar, D.P. Chauhan, S.P. Cherian, J.M. Carethers, T.A. Kunkel, and C.R. Bolard. Human chromosome 3 corrects micmatch repair deficiency and microsatellite instability and reduces N-Methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 54:4308-4312 (1994).
43. T. Uchida, C. Wada, C. Wang, H. Ishida, S. Egawa, E. Yokiyama, H. Ohtani, and E. Koshiba. Microsatellite instability in prostate cancer. Oncogene, 10:1019-1022 (1995).
44. M.R. Emmert-Buck, M.J. Roth, J. Teruya-Feldstein, L.J. Medeiros, W.G. Stetler-Stevenson, L.A. Liotta, and Z. Zhuang. Detection of nm23 microsatellite instability in microdissected human prostate cancer specimens. Lab. Invest. Abst. No. 427, 72:75A (1995).
45. K. Kunimi, U.S.R. Bergerheim, I-L. Larsson, P. Ekman, and V.P. Collins. Alllotyping of human prostatic adenocarcinoma. Genomics 11:530-536 (1991).
46. U.S.R. Bergerheim, K. Kumimi, V.P. Collins, and P. Ekman. Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Gene Chromosom. Cancer 3:215-220 (1993).
47. X. Gao, N. Wu, D. Grignon, W. Sakr, A.T. Porter, K.V. Honn. Allelic deletion of microsatellite loci on chromosome 6p in a subset of human prostate cancer. Cancer Mol. Biol. 1:297-304 (1994).
48. Sdi1/CIP1 WAF1. EMBO J. 14:555-563 (1995).
49. J.W. Harper, S.J. Elledge, K. Keyomarsi, B. Dynlacht, L.-H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, M.P. Fox, and N. Wei. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell. 6:387-400 (1995).
50. X. Gao, Y.Q. Chen, N. Wu, D.J. Grignon, W. Sakr, A.T. Porter, K.V. Honn. Somatic mutations of the WAF1/CIP1 gene in primary prostate cancer. Oncogene 11:1395-1398 (1995).
51. A. Elbendary, A. Berchuck, P. Davis, L. Havrilesky, R.C. Jr. Bast, J.D. Iglehart, and J.R. Marks. Transforming growth factor b1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Grow. Different. 5:1301-1307 (1994).
52. M.S. Sheikh, X.-S. Li, J.-C. Chen, Z.-M. Shao, J.V. Ordonez, and J.A. Fontana. Mechanisms of regulation of Waf1/CIP1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 9:3407-3415 (1994).
53. H. Jiang, J. Lin, Z.-Z. Su, R.R. Collart, E. Huberman, and P.B. Fisher. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9:3397-3406 (1994).
54. R.A. Steinman, B. Hoffman, A. Iro, C. Cuilouf, D.A. Liebermann, and M.E. El-Houseini. Induction of p21 (WAF-1/CIP1) during differentiation. Oncogene 9:3389-3396 (1994).
55. W. Zhang, L. Graso, C.D. McClain, A.M. Gambel, Y. Cha, S. Travali, A.B. Deisseroth, and W.E. Mercer. p53-independent induction of WAF/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res. 55:668-674 (1995).
56. O. Halevy, B.G. Novitch, D.B. Spicer, S.X. Skapek, J. Rhee, G.J. Hannon, D. Beach, A.B. and Lassar. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Washington DC) 267:1018-1021 (1995).
57. Cip1 in muscle and other terminally differentiation cells. Science (Washington DC) 267:1024-1027 (1995).
58. W.S. El-Deiry, T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, E. Mercer, K.W. Kinzler, and B.Vogelstein. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825 (1993).
59. J.W. Harper, G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. The p21 Cdk-interaction protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75:805-816 (1993).
60. J. Chen, P.K. Jackson, M.W. Kirchner, and A. Dutta. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature (Lond.) 374:386-388 (1995).
61. J. Trapman, H.F.B.M. Sleddens, M.M. van der Weiden, W.N.M. Dinjens, J.J. Konig, F.H. Schroder, P.W. Faber, and F.T. Bosman. Loss of heterozygosity of chromo-some 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res. 54:6061-6064 (1994).
62. G.S. Bova, B.S. Carter, M.J.G. Bussemakers, M. Emi, Y. Fujiwara, N. Kyprianou, S.C. Jacobs, J.C. Robinson, J.I. Epstein, P.C. Walsh, W.B. Isaacs. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res. 53:3869-73 (1993).
63. D. Macgrogan, A. Levy, D. Bostwick, M. Wagner, D. Wells, and R. Bookstein. Loss of chromosome arm 8p loci in prostate-cancer-mapping by quantitative allelic imbalance. Gene Chrom Cancer 10:151-159 (1994).
64. H. Matsuyama, Y. Pan, L. Skoog, B. Tribukait, K. Naito, P. Ekman, P. Lichter, U.S.R. Bergerheim. Deletion mapping of chromosome 8p in prostatecancer by fluorescence in situ hybridization. Oncogene 9:3071-3076 (1994).
65. J. Kagan, J. Stein, R.J. Babaian, Y.-S. Joe, L.L. Pisters, A.B. Glassman, A.C. von Eschenbach, and P. Troncoso. Homozygous deletion at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 11:2121-2126 (1995).
66. G.S. Bova, M.J.G. Bussmakers, J.C. Robinson, D. MacGrogan, A. Levy, R. Bookstein, and W.B. Isaacs. Homozygous deletion mapping of a one m egabase region of 8p22 in a human prostate cancer. Abst. Book, Basic and clinical aspects of prostate cancer, Palm Springs, CA, USA, Abstract No. A-4, December 8-12 (1994).
67. J. C. Zenklusen, C. Thompson, P. Troncoso, J. Kagan, and C.J. Conti. Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppre-ssor gene at 7q31.1. Cancer Res. 54:6370-6373 (1994).
68. C.W. Rinker-Schaeffer, A.L. Hawkins, N. Ru, J. Dong, G. Stoica, C.A. Griffin, T. Ichikawa, J.C. Barrett, J.T. Isaacs. Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11. Cancer Res. 54:62-49-6256 (1994).
69. K.A. Cooney, J.C. Wetzel, S.D. Merajver, J.A. Macoska, T.P. Singleton, and K.J. Wojno. Distinct regions of allelic loss on Bq in prostate cancer. Cancer Res. 56:1142-1145 (1996).
70. J.T. Dong, P.W. Lamb, C.W. Rinker-Schaeffer, J. Vukanovic, T. Ichikawa, J.T. Isaacs, and J.C. Barrett. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science (Washington DC) 268:884-6 (1995).
71. X. Gao, A. Zacharek, A. Salkowski, D. Grignon, W. Sakr, A.T. Porter, and K.V. Honn. Loss of heterozygosity of the BRCA1 and other loci on chromosome 17q in human prostate cancer. Cancer Res. 55:1002-1005 (1995).
72. X. Gao, A. Zacharek, D. Grignon, W. Sakr, A.T. Porter, and K.V. Honn. Localiza-tion of potential tumor suppressor loci to a <2 Mb region on chromosome 17q in human prostate cancer. Oncogene 11:1241-1247 (1995).
73. S.L. Parker, T. Tong, S. Bolden, and P.A. Wingo. Cancer statistics 1996. Ca Cancer J Clin. 65:5-27 (1996).
74. A. Chiarodo. National cancer institute roundtable on prostate cancer: Future research directions. Cancer Res. 51:2498-2505 (1991).
75. M.B. Garnick. Prostate Cancer: Screening, diagnosis, and management. Ann Int Med 118:804-818 (1993).
76. K.V. Honn, D.G. Tang, X. Gao, I.A. Butovich, B. Lui, J. Timar, W. Hagmann. 12-Lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer Metastasis Rev. 13:365-396 (1994).
77. X. Gao, and K.V. Honn. 12-lipoxygenase and 12(S)-HETE in cancer invasion and metastasis. Adv. Oncol. 11(2):3-8 (1995).
78. X. Gao, and K.V. Honn. 12-lipoxygenase as a prostate cancer marker and therapeutic target. Adv. Oncol. 11(3):2-8 (1995).
79. X. Gao, D. Grignon, T. Chbihi, A. Zacharek, Y.Q. Chen, W. Sakr, A.T. Porter, J.D. Crissman, J.E. Pontes, I.J. Powell, and K.V. Honn. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urol. 46:227-237 (1995).